Vitamin K2 shows promise for childhood eczema
NCT ID NCT07574242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding vitamin K2 to standard treatment could improve symptoms in children aged 6–12 with moderate-to-severe atopic dermatitis (eczema). For 12 weeks, 100 children received either vitamin K2 or a placebo alongside their usual care. The main goal was to see if the vitamin reduced eczema severity, measured by a standard skin score.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
October 6 University
Giza, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?